Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for clinical trials of HRS9531 injection, a novel dual agonist targeting GIPR and GLP-1R, aimed at improving metabolic disorders and weight management [1] Group 1: Product Development - The HRS9531 injection is based on the active ingredient HRS9531, which has global independent intellectual property rights [1] - The drug is designed to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, leading to improved blood sugar levels and weight loss [1] Group 2: Target Indication - HRS9531 injection is expected to provide comprehensive benefits for patients with metabolic dysfunction-related fatty liver disease (MASH) by improving liver lipid accumulation, reducing inflammation, and potentially improving liver fibrosis [1] - There are currently no similar drugs approved for the MASH indication globally [1]